Seagen announced that 12- and 24-month progression free survival data will be presented for an ADCETRIS and immunotherapy combination in early and advanced stage classical Hodgkin lymphoma, respectively. The data will be featured in two oral presentations at the 65th American Society of HematologyAnnual Meeting & Exposition, taking place December 9-12, 2023 in San Diego. The ongoing Phase 2 clinical trial, SGN35-027, is evaluating ADCETRIS in combination with immunotherapy and chemotherapy. In addition, pre-clinical data will be presented for a next-generation novel CD30-directed antibody-drug conjugate (ADC), SGN-35C, that uses a topoisomerase I inhibitor payload. “These new data highlight our continued research and development focus on novel combinations to treat Hodgkin lymphoma and on next-generation CD30-directed therapies that aim to further improve outcomes while reducing treatment burden for patients,” said Roger Dansey, M.D., President, Research and Development and Chief Medical Officer at Seagen.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SGEN:
- Seagen reports Q3 EPS ($1.15) consensus (79c)
- Seagen Inc. (SGEN) Q3 Earnings Cheat Sheet
- Seagen CEO says nixed bladder cancer drug study due to IRA, Bloomberg reports
- Biotech Alert: Searches spiking for these stocks today
- Pfizer (NYSE:PFE) Slides despite EU Nod to Seagen Acquisition
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue